Ekso Bionics(TM) Gaining Ground in Neuro Rehabilitation for Veterans
Triple Order from Chicago VA Shows Clinical Role Expanding Within VA System
RICHMOND, Calif., October 14, 2014 -- Ekso Bionics Holdings, Inc. (OTCQB: EKSO), a robotic exoskeleton company, announced today that the Jesse Brown VA Medical Center in Chicago has ordered three Ekso GT™ robotic exoskeletons for use in general neuro-rehabilitation of patients with stroke, traumatic brain injury, and incomplete spinal cord injury. The most widely used robotic exoskeleton used in the clinical setting within VA systems, the Ekso GT robotic exoskeleton is uniquely designed to provide varying amounts of power to either side of the body. This allows patients with hemiplegia to get upright and walking early on in the rehabilitation process, which may result in the mitigation of compensatory behavior and gate deviations. Early clinical findings link early intervention with earlier discharge from acute rehabilitation facilities.
“To date, there are 8 Ekso GT robotic exoskeletons already being used for rehabilitation at Tampa VA (James A. Haley Veteran’s Hospital), Syracuse VA Medical Center, VA Boston Healthcare System, Hunter Holmes McGuire VA Medical Center and the Palo Alto VA System with additional Ekso suits scheduled for delivery and training to Chicago VA, Dallas VA, New Orleans VA and Oklahoma VA Systems," said co-founder Russ Angold, whose brother is a veteran and was paralyzed for a period of time. “This latest sale is a great next step in our progress of bringing the highest level of care to the VA system with best in class technology.”
Ekso Bionics designs, develops, and commercializes exoskeletons, or wearable robots, which have a variety of applications in the medical, military, industrial, and consumer markets. Exoskeletons are ready-to-wear, battery-powered robots that are strapped over the user’s clothing, enabling individuals to achieve mobility, strength, and endurance not otherwise possible. Ekso is forging a new frontier in rehabilitation for people living with the consequences of stroke, spinal cord injury and other neurological conditions affecting gait.
About Ekso Bionics
Since 2005, Ekso Bionics has been pioneering the field of robotic exoskeletons, or wearable robots, to augment human strength, endurance and mobility. The company's first commercially available product called Ekso has helped thousands of people living with paralysis take millions of steps not otherwise possible. By designing and creating some of the most forward-thinking and innovative solutions for people looking to augment human capabilities, Ekso Bionics is helping people rethink current physical limitations and achieve the remarkable.
Ekso Bionics is headquartered in Richmond, CA and is listed on the OTC QB under the symbol EKSO. To learn more about Ekso Bionics please visit us at www.eksobionics.com
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing, the significant length of time and resources associated with the development of our products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, volatility in the price of the Company's raw materials, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including, the Company's Current Report on Form 8-K/A filed on March 31, 2014 and the Company's latest Form 10-Q filed on August 8, 2014. The Company does not undertake to update these forward-looking statements.
CONTACT: Media Contact: Chantal Beaudry, Managing Director Phone: 646-871-8480 firstname.lastname@example.org Investor Contact: Lauren Glaser, Vice President Phone: 646.378.2972 email@example.comSource: Ekso Bionics
Released October 15, 2014